For The Public (SE) For The Public (IT) For The Public (DE) For The Public (FI) For The Public (CZ) For The Public (GR)
Home
About Us
Contact us
Consortium Description
Management
Research Partners
Partner Institutions
Research Activities
Summary
Dissemination of Knowledge
News
Contact
Press Releases
Events
FP6 Facts
For The Public
(Multilingual Content)
Project
News And Views
FP6

News: Press Releases: January 8th, 2007
Posted on Thursday, March 29 @ 15:27:11 EEST by admin
News European Scientists Receive Funding From Sixth EU Framework Program to develop novel therapy for cancer.

Scientists of a consortium led by the University of Crete Medical School, Greece, have been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new therapeutic strategies for cancer. The research program, code-named Apotherapy, will develop methods to activate a protein at the surface of ovarian, lung and bladder tumor cells which will stop their growth. This protein, called CD40, can also induce the destruction of malignant cells by the body’s own defences. The scientists who participate in the program aim to combine CD40 triggering with chemotherapy or with innovative drugs that will cut-off signals necessary for the survival of cancer cells. This strategy is expected to achieve maximal therapy with minimal side effects.

Dr Aristides Eliopoulos who co-ordinates the Apotherapy research program, commented: "We are delighted to have received funding under this program grant. It gives us the opportunity to collaborate with some of the top European scientists and oncologists to fight this deadly disease. We are confident that in the near future, we will be able to progress the best of our developed strategies into clinical practice for the benefit of cancer sufferers."

The project integrates the core skills and expertise of academic scientists, oncologists and biotechnology researchers from a total of seven Institutions:

University of CreteHeraklionGreece
University College LondonLondonUK
Istituto Mario NegriMilanItaly
University of HelsinkiHelsinkiFinland
University OlomoucOlomoucCzech Republic
University of UppsalaUppsalaSweden
Novosom AGHalleGermany


Apotherapy is supported with € 2 million from the European Commission FP6 for a period of 3 years.

Apotherapy: CD40 ligand-based modalities for the treatment of solid tumors

Apotherapy Contact:

Aristides Eliopoulos, PhD
Associate Professor
Molecular and Cellular Biology Laboratory
Basic Sciences Division, Rm 2B-12
University of Crete Medical School
71003 Heraklion, Crete Greece
Tel: +30 2810 394 565 or 819
Fax:+30 2810 394 530
email: eliopag@med.uoc.gr
 
 



Visitors:
Designed by: George Savakis for Virtual Medical Lab (Faculty of Medicine - Univercity of Crete)